Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...

In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on Merus (MRUS – Research Report), with a price ...

Andrew Berens, an analyst from Leerink Partners, maintained the Buy rating on Merus (MRUS – Research Report). The associated price target ...

Mirae Asset Global Investments Co. Ltd. increased its position in shares of Merus (NASDAQ:MRUS – Free Report) by 24.7% in the 3rd quarter, Holdings Channel.com reports. The fund owned 2,467 shares of ...

GET MORE AI-GENERATED SIGNALS: October 23, 2024, 07:32 am ET, BY Randall S.- Contributor| Editor: Thomas H. Kee Jr. ( Follow on LinkedIn) Short MRUS slightly under 59.06, target 51.8, stop loss @ ...

Despite the PDUFA date being extended by three months for Merus’ zenocutuzumab, Truist Securities analyst Asthika ...

Merus N.V. (MRUS) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $0.43 per share a year ago. These figures are ...

Hagan 1-4 0-0 2, Zapater 0-1 0-0 0, Mugosa 1-3 0-0 3, Potter 2-5 2-3 6, Williams 3-6 1-3 9, Whalen 1-2 0-0 2, Martin 5-9 0-0 12, Aubry-Thomas 0-6 2-2 2, Hansen 1-2 3-6 5, Wilson 3-5 0-0 7, ...

Idaho – which finished 11-21, with a 5-13 mark in the Big Sky – won half of its preseason games before coming up with some ...

Team Rebounds: 6. Team Turnovers: None. Blocked Shots: 4 (Crujeiras, Martin, Potter, Whalen). Turnovers: 19 (Whalen 4, Aubry-Thomas 3, Hagan 3, Mugosa 2, Potter 2, Williams 2, Hansen, Martin, Zapater) ...

Fintel reports that on October 24, 2024, UBS initiated coverage of Merus N.V. (NasdaqGM:MRUS) with a Buy recommendation. As of October 22, 2024, the average one-year price target for Merus N.V. is ...